Compare HBIO & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HBIO | LEXX |
|---|---|---|
| Founded | 1901 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.1M | 18.9M |
| IPO Year | 2000 | N/A |
| Metric | HBIO | LEXX |
|---|---|---|
| Price | $0.60 | $0.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $2.50 | $1.50 |
| AVG Volume (30 Days) | ★ 537.0K | 173.0K |
| Earning Date | 03-12-2026 | 04-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $87,371,000.00 | $522,000.00 |
| Revenue This Year | N/A | $13.35 |
| Revenue Next Year | $7.80 | $78.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 5.05 |
| 52 Week Low | $0.28 | $0.46 |
| 52 Week High | $1.43 | $1.90 |
| Indicator | HBIO | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 54.16 | 42.52 |
| Support Level | $0.53 | $0.67 |
| Resistance Level | $0.65 | $0.79 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 69.66 | 29.36 |
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.